As the COVID-19 pandemic has put severe stress and strain on the capacity of hospitals around the world, concerted efforts have been made to evaluate therapeutics aimed at preventing the need for mechanical ventilation.

The dissemination of information about potential therapeutic options through various media platforms has been swift and unprecedented.

Although the goal of sharing through non-traditional channels might be to accelerate the implementation of therapeutic approaches, some of this information is low-quality evidence that has not been peer-reviewed and is subject to bias.

Should reservations about the adoption of potentially beneficial interventions be relaxed in the context of a pandemic?

What threshold of evidence is needed for simple, apparently safe, low-technology, or low-cost interventions in the absence of effective treatments?

Read More